TOP HEADLINES

Featured Story

  • UPenn researchers develop nanogel for mitigating lung inflammation

    Researchers at the University of Pennsylvania said they have uncovered a delivery method to treat acute pulmonary inflammation, a condition that afflicts patients suffering from multiple blood transfusions, sepsis, lung surgery and acute lung trauma and has a mortality rate as high as 40%.

Most absorbent material on Earth gives poorly soluble drugs a boost

A record-breaking material discovered last year by Swedish researchers has passed another milestone for drug delivery, showing it can hold poorly soluble drugs and, down the road, deliver them with a fast dissolution rate.

MIT engineers discover key mechanism behind gold nanoparticle delivery

Gold nanoparticles are once again in the drug delivery spotlight as MIT scientists have discovered a mechanism by which the particles enter cells and could thus act as better drug carriers.

Patent Office grants Alnylam new claims on its RNAi delivery method

Alnylam announced July 22 that its intellectual property estate has been strengthened due to the U.S. Patent Office's issuance of a Notice of Allowance for claims in one of its patent applications that covers "chemically modified RNA therapeutics conjugated with an N-acetylgalactosamine (GalNAc) ligand independent of length, sequence, or disease target," according to a statement. 

Titan Phase III trial for subdermal implant begins enrollment

A year after the FDA rejected Titan Pharmaceutical's Probuphine subdermal implant for the treatment of opioid dependence, the company is knocking on the approval door once again. It announced July 21 that the first patients have enrolled in its Phase III trial designed to address the FDA's questions.

Galena Biopharma to market anti-vomit oral soluble film to cancer patients

Galena Biopharma believes that its experienced oncology sales team will enable it to effectively market Zuplenz, the only oral soluble film for preventing vomiting following chemotherapy and radiotherapy, which it will soon offer thanks to a licensing agreement struck with MonoSol Rx, the developer of the product's delivery technology.

MORE NEWS

From Our Sister Sites

FierceBiotech Research

In response to back-to-back incidents involving government laboratories, a top official at the U.S. Centers for Disease Control and Prevention has resigned, and the agency has assembled a safety board to address concerns that have arisen after workers were potentially exposed to anthrax and H5N1 flu.

FiercePharma

Merck is going through a complete makeover, buying and selling units at a rapid pace. And some of its employees are getting caught in its "out with the old and in with the new" philosophy. Now 600 sales reps have been told their services are no longer needed